Skip to content

Author

Hong-Xu Liu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial.

INTRODUCTION In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC). Here, report prespecified patien...

D. Yue, F. Cappuzzo, Wen-Xiang Wang et al. · 0 citations
Review Oct 2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

BACKGROUND Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...

Chong-Rui Xu, Yan Zhang, G. Lin et al. · 1 citation
Review Aug 2026

Biomimetic lung-targeted nano drug delivery systems: From chemical biology to respiratory disease therapy.

Respiratory diseases represent a severe global health burden. However, the clinical efficacy of conventional therapeutics is severely limited by complex pulmonary physiological barriers, including mucociliary clearance, alveolar-capillary barrier, and alveolar macrophage phagocytosis. Biomimetic nano drug delivery syst...

Shao-Huang Wu, Bingyi Lu, Hanjie Chen et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.